Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up.

[1]  Jun Zhu,et al.  A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type , 2013, Journal of Hematology & Oncology.

[2]  Y. Xia,et al.  First‐line combination of gemcitabine, oxaliplatin, and L‐asparaginase (GELOX) followed by involved‐field radiation therapy for patients with stage IE/IIE extranodal natural killer/T‐cell lymphoma , 2013, Cancer.

[3]  Hui-Qiang Huang,et al.  Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients , 2012, International Journal of Hematology.

[4]  R. Suzuki,et al.  Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Q. Cai,et al.  Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience , 2011, Leukemia & lymphoma.

[6]  P. Gaulard,et al.  Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. , 2011, Blood.

[7]  K. Ohshima,et al.  Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Jiade J Lu,et al.  Variable Clinical Presentations of Nasal and Waldeyer Ring Natural Killer/T-Cell Lymphoma , 2009, Clinical Cancer Research.

[9]  Biyun Wang,et al.  Immunohistochemical expression and clinical significance of P‐glycoprotein in previously untreated extranodal NK/T‐cell lymphoma, nasal type , 2008, American journal of hematology.

[10]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  İ. Zindancı,et al.  Extranodal NK/T cell lymphoma, nasal type. , 2008, European journal of dermatology : EJD.

[12]  Jiyan Liu,et al.  Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. , 2008, International journal of radiation oncology, biology, physics.

[13]  C. Copie-Bergman,et al.  Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  S. Schuster,et al.  Selective apoptosis of natural killer‐cell tumours by l‐asparaginase , 2005, British journal of haematology.

[15]  J. Roh,et al.  Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Bates,et al.  P‐glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines , 1991, International journal of cancer.